Arvinas, Inc.ARVN
NASDAQ • Healthcare
$9.72
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-91.7% YoY
Gross Margin
53.2%
Health Score
3/10
D/E Ratio
0.02
Confidence
LOW
Business Snapshot
Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies, specifically PROTACs (proteolysis targeting chimeras), which represent a novel therapeutic modality. The company operates in the highly competitive oncology and neurodegenerative disease space, where it is a pioneer in targeted protein degradation but faces numerous well-capitalized rivals including major pharmaceutical entrants. With trailing twelve-month revenue of $89.4 million, Arvinas is a small-cap biotech that has not yet achieved commercial profitability and relies heavily on partnership revenues and equity financing. The defining characteristic of this company is its platform technology for degrading disease-causing proteins, which carries high binary risk typical of early-stage drug developers where pipeline success or failure dictates valuation.
Financial Health
Gross margin stands at 53.2%, a dramatic decline from 441.1% in the prior year, reflecting the lumpy nature of partnership revenue recognition rather than core operational deterioration. The net margin of -30.8% indicates persistent operating losses, with TTM net income of -$221.3 million...
Risk Assessment
- EARNINGS QUALITY — The company beat estimates in 3 of 4 recent quarters, which typically signals guidance credibility; however, the underlying business is still deeply unprofitable and revenue is highly volatile due to milestone dependence.
- REVENUE DECELERATION — Revenue declined 91.7% year-over-year, a dramatic reversal from prior periods that reflects the non-recurring nature of milestone-based revenue and raises questions about revenue sustainability.
- 52-WEEK POSITION — The current price of $9.72 sits below the midpoint of the 52-week range ($10.21), and is 33.0% below the 52-week high of $14.51, indicating the stock remains under pressure from its recent highs.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- FCF / CASH BURN — Free cash flow is negative at -$275.7 million, implying the company is burning significant cash to fund operations and will need to raise additional capital....